Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAaron D. SchimmerKYKaren YeeHSHassan Sibai

Discussion

Loading...

Member takes

Overview

Findings show MFC-MRD predicts prognosis in FLT3-ITD AML, suggesting implications for chemotherapy.

Key Points

  • Evaluating the prognostic value of MFC-based MRD assessment in FLT3-ITD AML patients considering concurrent mutations.
  • Evaluated 111 AML patients with FLT3-ITD
  • Compared survival outcomes by MFC-MRD status and co-mutation profile
  • Used Kaplan-Meier method and Cox models for survival analysis.
  • MFC-MRD negativity associated with improved relapse-free survival
  • Two-year overall survival rate was 55.6%
  • Midostaurin was administered to a majority of chemotherapy patients.

Cite This Study

Schimmer et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c9https://doi.org/10.1182/blood-2025-7051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  2. 2Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  3. 3Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025
  4. 4The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.2025
  5. 5Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis2026